

RESEARCH LETTER



Advance Care Planning and End-of-Life Education in Heart Failure: Insights From the NCDR PINNACLE Registry

Casey E. Cavanagh¹ PhD; Lindsey Rosman¹ PhD; Philip Chui, MD; Karl Minges, PhD, MPH; Nihar R. Desai¹ MD, MPH; Sarah Goodlin, MD; Savitri Fedson¹ MD; John A. Spertus¹ MD, MPH; Ty J. Gluckman¹ MD; Yang Song, MS; Luke Zheng¹ BS; Alexander Turchin¹ MD, MS; Gheorghe Doros, PhD; Jane J. Lee, PhD; Matthew M. Burg¹ PhD

Advance care planning (ACP) and prognosis/end-of-life (EOL) education are recommended by several professional organizations and consensus guidelines in heart failure (HF) care.¹ Yet, these occur infrequently in HF care.^{2,3}

A primary goal of the PINNACLE (Practice Innovation and Clinical Excellence) Registry was to track critical measures of quality improvement and outcomes. For HF, ACP and EOL education were identified as critical measures with education provided to clinicians. Given guidelines suggesting the importance of these metrics in HF care, data on ACP and EOL education were collected. Therefore, we examined (1) prevalence of ACP and EOL education in patients with HF and (2) variation in these metrics by patient, clinic, and provider characteristics.

The data utilized in this research were obtained from the American College of Cardiology Foundation's (ACCF) National Cardiovascular Data Registry (NCDR). Data are not publicly available, but requests for analyses can be submitted to the PINNACLE R&P Committee. Analyses are conducted by contracted Data Analytic Centers, which then provide aggregated and de-identified results to the stakeholder who submitted the research proposal.

Patients with HF (n=1 684 284) enrolled in the PINNACLE Registry, a prospective cohort for a range of cardiovascular conditions that are collected from 348 US outpatient academic and nonacademic cardiology practices from January 1, 2013 through June 30, 2018, were identified. Advarra approved this study and granted

a waiver of written informed consent. An electronic medical record mapping algorithm is used to capture variables of interest and relevant data, although paper-based reporting forms may also be used. Data were limited to those documented and inputted into the registry by each participating practice. χ^2 for categorical variables and *t* tests for continuous variables were used. All analyses were performed using SAS Version 9.4 (SAS Institute, Cary, NC) by the Baim Institute for Clinical Research.

Rates of and variation in ACP and EOL education were calculated for 1 675 458 HF outpatients (see Table 1).

Documentation of ACP was found for 34.1% of patients ($Mean_{age} = 68.9 \pm 14.1$). Documentation of ACP was low among patients with left ventricular assist device (34.1%) or other cardiovascular implantable electronic devices (pacemaker, 35.2%; ICD, 30.6%; CRT, 35.2%; CRT-D, 35.9%). Although a high rate of missingness, less than half of patients with New York Heart Association (NYHA) I–III HF (42–47%) had ACP documented compared with a higher rate among NYHA class IV (60.0%).

Documentation of EOL education was exceedingly low, occurring in only 1.9% of patients, with similar rates for men and women (1.9%), but lower among Hispanic/Latinos patients (0.3%), and Black patients (1.6%) compared with non-Hispanic/Latino patients (2.0%), and White patients (2.5%). Documented EOL education was low among patients with NYHA class III (2.5%) or IV (1.4%) HF, although there was a high rate of missingness. Similarly, documentation was low among patients

Key Words: advance care planning ■ communication ■ decision making ■ heart failure ■ prognosis

Correspondence to: Casey E. Cavanagh, PhD, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Behavioral Medicine Clinic, PO Box 800223, Charlottesville, VA 22908. Email casey.cavanagh@virginia.edu

For Sources of Funding and Disclosures, see page 76.

© 2022 The Authors. *Circulation* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Circulation: Cardiovascular Quality and Outcomes is available at <http://www.ahajournals.org/journal/circoutcomes>

Nonstandard Abbreviations and Acronyms

| | |
|-------------|---|
| ACCF | American College of Cardiology Foundation |
| ACP | advance care planning |
| EOL | end of life |
| HF | heart failure |
| NCDR | National Cardiovascular Data Registry |
| NYHA | New York Heart Association |

Table 1. Rates of ACP and EOL within Patient, Provider, and Practice Characteristics

| Patient characteristics | ACP | EOL | Missing |
|-----------------------------|------|------|---------|
| Sex | | | 0.0 |
| Men | 33.6 | 1.9 | |
| Women | 34.3 | 1.9 | |
| Race | | | 28.1 |
| White | 34.0 | 2.5 | |
| Black | 33.7 | 1.6 | |
| Other | 22.8 | 0.6 | |
| Ethnicity | | | 0.0 |
| Not Hispanic/Latino | 33.7 | 2.0 | |
| Hispanic/Latino | 38.4 | 0.3 | |
| Current smoker | 36.0 | 1.5 | 7.2 |
| Insurance | | | 26.1 |
| Private | 35.4 | 1.7 | |
| Medicare | 35.3 | 1.0 | |
| Medicaid | 37.8 | 0.4 | |
| Other | 31.8 | 0.2 | |
| None | 59.2 | 48.0 | |
| Comorbidities | | | 0.0 |
| Dyslipidemia | 34.3 | 2.2 | |
| Diabetes | 32.9 | 0.2 | |
| Hypertension | 34.2 | 2.1 | |
| Myocardial infarction | 35.4 | 2.2 | |
| PCI/PTCA | 39.1 | 2.1 | |
| CABG | 38.8 | 2.7 | |
| Stroke/TIA | 38.2 | 0.8 | |
| Cardiac events | | | 0.0 |
| LVAD | 34.1 | 0.0 | |
| CRT | 35.2 | 1.3 | |
| CRT-D | 35.9 | 1.3 | |
| ICD | 30.6 | 1.7 | |
| Permanent pacemaker | 35.2 | 1.4 | |
| MAGGIC risk score quartiles | | | 95.2 |
| 0–11 | 49.2 | 3.8 | |
| 12–16 | 53.4 | 3.8 | |
| 17–21 | 53.2 | 3.4 | |
| 22–45 | 51.6 | 2.4 | |

(Continued)

Table 1. Continued

| Patient characteristics | ACP | EOL | Missing |
|--|------|-----|---------|
| MAGGIC risk score quartiles without NYHA | | | 88.9 |
| 0–12 | 41.1 | 2.7 | |
| 13–17 | 42.9 | 2.0 | |
| 18–21 | 43.7 | 1.6 | |
| 22–42 | 42.0 | 1.1 | |
| NYHA class | | | 58.7 |
| Class I | 42.1 | 3.5 | |
| Class II | 46.5 | 4.3 | |
| Class III | 43.8 | 2.5 | |
| Class IV | 60.0 | 1.4 | |
| Heart failure first diagnosed ≥ 18 months ago | 29.9 | 1.3 | 0.0 |
| Beta blocker | 33.5 | 1.7 | 0.0 |
| ACEi/ARB | 33.5 | 1.5 | 0.0 |
| Provider/Practice characteristics | | | |
| Provider type | | | 0.0 |
| Physician | 33.8 | 2.0 | |
| Nurse practitioner | 37.2 | 1.7 | |
| Other | 31.8 | 1.1 | |
| Geographic region | | | 0.0 |
| Northeast | 35.3 | 0.1 | |
| South region | 32.2 | 1.5 | |
| Midwest | 42.8 | 6.0 | |
| West region | 29.0 | 0.3 | |
| Location | | | 0.1 |
| Urban | 37.5 | 3.7 | |
| Suburban | 31.8 | 0.4 | |
| Rural | 29.3 | 1.1 | |

Data presented are in percentages unless otherwise indicated. ACEi/ARB indicates angiotensin converting enzyme inhibitors/angiotensin receptor blocker; ACP, advanced care planning; CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; EOL, end-of-life education; ICD, implantable cardioverter defibrillator; LVAD, left ventricular assist device; MAGGIC, meta-analysis global group in chronic heart failure; NYHA, New York Heart Association; PCI/PCTA, percutaneous coronary intervention/percutaneous transluminal coronary angioplasty; TIA, transient ischemic attack.

with cardiovascular implantable electronic devices (pace-maker, 1.4%; ICD, 1.7%; CRT, 1.3%; CRT-D, 1.3%).

Despite the importance of ACP and EOL discussions in patients with HF, this large contemporary outpatient evaluation reveals modest rates of ACP (<50%) and very low rates of EOL education (<2%), with substantial variation by patient and practice characteristics. Of note, there was little evidence of appreciably greater discussion in those with a poor prognosis, including those who were NYHA class III/IV, although the association is unclear given the high rates of missingness. These findings suggest that despite guideline recommendations, patients with HF have infrequently documented (and potentially infrequently received) ACP or EOL education, which may adversely affect a patient's ability to engage in informed

decision making. This is particularly important given the unpredictable disease trajectory of HF and the need for multiple treatment decisions by patients with advanced HF, increasing the likelihood that they may lack the knowledge and understanding to make these decisions.

Additionally, results from this study suggest a disconnect between consensus guidelines and routine clinical care, despite potential benefits by various stakeholders. Several factors may contribute to variation in ACP and EOL education, including access to care, provider time and resources, as well as provider confidence in these discussions. Future work is needed to understand these factors and improved ways by which to implement guideline-directed HF care. A multidisciplinary model which addresses barriers to care, such as limited care communication among team members, may help with ACP and EOL education. In addition, training in discussing ACP and EOL education be of great help to clinicians.⁴ Increasing the amount of time and resources available to facilitate these discussions may also assist with improved reimbursement for care coordination and related interventions. Future research should test implementation efforts to increase engagement in these care aspects.

ARTICLE INFORMATION

Affiliations

Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA (C.E.C.). Department of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill, Chapel Hill, NC (L.R.). Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.C., K.M., N.R.D., M.M.B.). Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, CT (K.M., N.R.D.). Department of Health Administration & Policy, University of New Haven, West Haven, CT (K.M.). VA Portland Healthcare System and Department of Medicine, Oregon Health & Science University, Portland, OR (S.G.). Micheal E DeBaKey VA Medical Center, Department of Medicine, Baylor College of Medicine, Center for Medical Ethics and Health Policy, Baylor College of Medicine,

Houston, TX (S.F.). Department(s) of Biomedical and Health Informatics and Internal Medicine, Section of Cardiovascular Disease, University of Missouri-Kansas City and Saint Luke's Mid America Heart Institute, Kansas City, MO (J.A.S.). Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR (T.J.G.). Baim Institute for Clinical Research, Boston, MA (Y.S., L.Z., A.T., G.D., J.J.L.). Harvard Medical School, Boston, MA (A.T.). Division of Endocrinology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (A.T.). Department of Biostatistics, Boston University, MA (G.D.). Department of Anesthesiology, Yale School of Medicine, New Haven, CT (M.M.B.).

Sources of Funding

This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR). The views expressed in this article represent those of the author(s), and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR. For more information go to CVQuality.ACC.org/NCDR or email ncdrresearch@acc.org.

Disclosures

Dr. Cavanagh's effort was partially sponsored by HSR&D post-doctoral fellowship VA Office of Academic Affairs. One of the authors, Dr. Alexander Turchin, reports no disclosures related to this study, but reports the following relationships with industry: Dr. Turchin reports equity in Brio Systems. Dr. Turchin also reports receiving research support from Patient Centered Outcomes Research Institute, Astra Zeneca, Eli Lilly, Novo Nordisk and Sanofi. In addition, Dr. Rosman's effort was sponsored by a grant from the National Heart, Lung, and Blood Institute (K23HL141644). Dr. Rosman reports consultancy fees from Pfizer and Biotronik. No other authors report financial relationships with industry.

REFERENCES

- McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368
- Ahluwalia SC, Levin JR, Lorenz KA, Gordon HS. "There's no cure for this condition": how physicians discuss advance care planning in heart failure. *Patient Educ Couns*. 2013;91:200–205. doi: 10.1016/j.pec.2012.12.016
- Butler J, Binney Z, Kalogeropoulos A, et al. Advance directives among hospitalized patients with heart failure. *JACC Hear Fail*. 2015;3:112–121. doi: 10.1016/j.jchf.2014.07.016
- Back AL, Anderson WG, Bunch L, Marr LA, Wallace JA, Yang HB, Arnold RM. Communication about cancer near the end of life. *Cancer*. 2008;113(7 suppl):1897–1910. doi: 10.1002/cncr.23653